Litcius/Paper detail

Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial

Amer M. Zeidan, Kiyoshi Ando, Odile Beyne Rauzy, Mehmet Turgut, Ming‐Chung Wang, Roberto Cairoli, Hsin‐An Hou, Yok‐Lam Kwong, Montserrat Arnán, Stef Meers, Vinod Pullarkat, Valeria Santini, Kamel Malek, Flavia Kiertsman, Julie Niolat, Pedro Marques Ramos, Hans D. Menssen, Pierre Fenaux, Yasushi Miyazaki, Uwe Platzbecker

2023The Lancet Haematology67 citationsDOI

Topics & Concepts

MedicineAzacitidineDecitabineInternal medicineDiscontinuationMyelodysplastic syndromesPlaceboHypomethylating agentClinical endpointAdverse effectOncologyRandomized controlled trialGastroenterologyBone marrowPathologyChemistryBiochemistryGene expressionGeneAlternative medicineDNA methylationAcute Myeloid Leukemia ResearchCAR-T cell therapy researchImmune cells in cancer
Sabatolimab plus hypomethylating agents in previously untreated patients with higher-risk myelodysplastic syndromes (STIMULUS-MDS1): a randomised, double-blind, placebo-controlled, phase 2 trial | Litcius